Skip to main content
SpringerLink
Log in

Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

The histologic differential diagnosis between intramuscular myxoma and low-grade myxofibrosarcoma can be quite difficult in some cases. To identify a diagnostic immunohistochemical marker, we compared the staining profiles of 19 different antigens, including cell cycle proteins, apoptosis proteins, and proliferative markers, and selected other signaling and structural proteins in these two tumors. Ten cases each of intramuscular myxoma and low-grade myxofibrosarcoma were stained with antibodies directed against apoptosis regulatory proteins (Bcl2, activated caspase-3, phospho-H2A.X, and cleaved PARP), cell cycle regulatory proteins (Rb1, Cyclin-A, CDKN1B, and Cdt1), proliferative markers (KI67, MCM2, phospho-histone H3, and geminin), cell signalling molecules (c-Myc, EGF, EGFR, PLA2G4A, and HSP90), a dendritic cell marker (CD209), and the extracellular matrix proteoglycan decorin. Staining patterns of myxoma and myxofibrosarcoma were compared using Fisher’s exact test and the Mann-Whitney test. For each potential diagnostic marker studied, the proportions of cases scored as positive on both dichotomous or ordinal scales were not significantly different between myxoma and myxofibrosarcoma. Myxoma and myxofibrosarcoma share a common immunophenotype for each of the markers studied. Distinction between these tumors is still predominantly based on morphologic criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, O’Donnell P, Skinner JA, Tirabosco R, Flanagan AM (2009) GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol 22:718–724

    Article  CAS  PubMed  Google Scholar 

  2. Graadt van Roggen JF, Hogendoorn PC, Fletcher CD (1999) Myxoid tumours of soft tissue. Histopathology 35:291–312

    Article  CAS  PubMed  Google Scholar 

  3. Huang HY, Huang WW, Wu JM, Huang CK, Wang JW, Eng HL, Lin CN, Chou SC, Yu SC, Fang FM, Lee JC, Li CF (2008) Flow cytometric analysis of DNA ploidy and S-phase fraction in primary localized myxofibrosarcoma: correlations with clinicopathological factors, Skp2 expression, and patient survival. Ann Surg Oncol 15:2239–2249

    Article  PubMed  Google Scholar 

  4. Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, Hsiung CY (2006) Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 12:487–498

    Article  CAS  PubMed  Google Scholar 

  5. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR (2004) Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 35:612–621

    Article  PubMed  Google Scholar 

  6. Huang HY, Li CF, Fang FM, Tsai JW, Li SH, Lee YT, Wei HM (2010) Prognostic implication of ezrin overexpression in myxofibrosarcomas. Ann Surg Oncol 17:3212–3219

    Article  PubMed  Google Scholar 

  7. Kempson RL, Fletcher CD, Evans HL, Hendrickson MR, Sibley RK (2001) Intramuscular myxoma. In: Tumors of the soft tissues. Atlas of tumor pathology, Third Series, Fascicle 30. Armed Forces Institute of Pathology, Washington, D.C., pp 419–423

  8. Kempson RL, Fletcher CD, Evans HL, Hendrickson MR, Sibley RK (2001) Myxoid variant malignant fibrous histiocytoma (Myxofibrosarcoma). Tumors of the soft tissues. Atlas of tumor pathology, Third Series, Fascicle 30. Armed Forces Institute of Pathology, Washington, D.C., pp 166–172

  9. Li CF, Huang HY, Wu WR, Liang SS, Chen YL, Chen LR, Peng YT, Lee HC, Shiue YL (2014) Clinical aggressiveness of myxofibrosarcomas associates with down-regulation of p12CDK2AP1: prognostic implication of a putative tumor suppressor that induces cell cycle arrest and apoptosis via mitochondrial pathway. Ann Surg Oncol 21:711–720

    Article  Google Scholar 

  10. Li CF, Wang JM, Kang HY, Huang CK, Wang JW, Fang FM, Wang YH, Wu WR, Li SH, Yu SC, Lee JC, Lan J, Shiue YL, Wu LC, Huang HY (2012) Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res 18:1598–1610

    Article  CAS  PubMed  Google Scholar 

  11. Meis-Kindblom JM, Sjogren H, Kindblom LG, Peydro-Mellquist A, Roijer E, Aman P, Stenman G (2001) Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch 439:141–151

    Article  CAS  PubMed  Google Scholar 

  12. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD (1996) Myxofibrosarcoma: clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20:391–405

    Article  CAS  PubMed  Google Scholar 

  13. Mentzel T, Hogendoorn PC, Huang H-Y (2013) Myxofibrosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F (eds) WHO classification of tumours of soft tissue and bone. IARC, Lyon, pp 93–94

    Google Scholar 

  14. Nielsen GP, Hogendoorn PC (2013) Intramuscular myxoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F (eds) WHO classification of tumours of soft tissue and bone. IARC, Lyon, pp 195–196

    Google Scholar 

  15. Nielsen GP, O’Connell JX, Rosenberg AE (1998) Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Am J Surg Pathol 22:1222–1227

    Article  CAS  PubMed  Google Scholar 

  16. Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Kinukawa N, Iwamoto Y, Tsuneyoshi M (2003) Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 34:1035–1042

    Article  CAS  PubMed  Google Scholar 

  17. Okamoto S, Hisaoka M, Ushijima M, Nakahara S, Toyoshima S, Hashimoto H (2000) Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch 437:133–137

    Article  CAS  PubMed  Google Scholar 

  18. Sington JD, Freeman A, Morris LS, Vowler SL, Arch BN, Fisher C, Coleman N (2004) Minichromosome maintenance protein in myxofibrosarcoma. Mod Pathol 17:235–240

    Article  CAS  PubMed  Google Scholar 

  19. Soilleux EJ, Rous B, Love K, Vowler S, Morris LS, Fisher C, Coleman N (2003) Myxofibrosarcomas contain large numbers of infiltrating immature dendritic cells. Am J Clin Pathol 119:540–545

    Article  PubMed  Google Scholar 

  20. Suster S, Fisher C, Moran CA (1998) Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 22:863–872

    Article  CAS  PubMed  Google Scholar 

  21. Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, Yu SC, Lan J, Huang HY (2012) Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol 19:2716–2725

    Article  PubMed  Google Scholar 

  22. van Roggen JF, McMenamin ME, Fletcher CD (2001) Cellular myxoma of soft tissue: a clinicopathological study of 38 cases confirming indolent clinical behaviour. Histopathology 39:287–297

    Article  PubMed  Google Scholar 

  23. Walther I, Walther BM, Chen Y, Petersen I (2014) Analysis of GNAS1 mutations in myxoid soft tissue and bone tumors. Pathol Res Pract 210:1–4

    Article  CAS  PubMed  Google Scholar 

  24. Wang T, Goodman MA, McGough RL, Weiss KR, Rao UN (2014) Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. Int J Surg Pathol 22:589–599

    Article  CAS  PubMed  Google Scholar 

  25. Weiss SW, Enzinger FM (1977) Myxoid variant of malignant fibrous histiocytoma. Cancer 39:1672–1685

    Article  CAS  PubMed  Google Scholar 

  26. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R (2006) Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 19:407–416

    Article  PubMed  Google Scholar 

  27. Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-de Bruijn IH, Knijnenburg J, Cleton-Jansen AM, Sciot R, Fletcher CD, Deelder AM, Szuhai K, Hensbergen PJ, Hogendoorn PC (2009) Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 13:1291–1301

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Funding

The authors have no relevant sources of funding to report.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Medical Center North, CC-3322 1161 21st Ave. South, Nashville, TN, 37232, USA

    Justin M. M. Cates

  2. Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

    Vincent A. Memoli

  3. Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA

    Raul S. Gonzalez

Authors
  1. Justin M. M. Cates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent A. Memoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raul S. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin M. M. Cates.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cates, J.M.M., Memoli, V.A. & Gonzalez, R.S. Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma. Virchows Arch 467, 211–216 (2015). https://doi.org/10.1007/s00428-015-1778-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-015-1778-8

Keywords

Search

Navigation